Physician profile
John K Hill
NPI 1780646992
$2,450.05
in general payments reported to CMS, 2019-2025
43 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $389 · 2021: $179 · 2022: $488 · 2023: $143 · 2024: $20.98 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $396 · Food and Beverage: $64.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $395.89 |
| Food and Beverage | $64.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $312.70 | 2019-2022 | |
| Seagen INC. | $207.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.18 | 2019-2025 | Lynparza |
| Pfizer INC. | $178.96 | 2019-2022 | |
| Astellas Pharma US INC | $174.01 | 2020-2023 | Padcev |
| Genentech USA, INC. | $134.22 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $111.26 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $109.74 | 2019-2022 | |
| Celgene Corporation | $88.89 | 2019-2022 | |
| Genzyme Corporation | $65.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.78 | 2019-2020 | |
| Incyte Corporation | $57.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $55.53 | 2019-2023 | Libtayo |
| Gilead Sciences, INC. | $50.92 | 2019-2022 | |
| Lilly USA, LLC | $50.48 | 2019-2024 | Zepbound, Jardiance |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.